Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions

Radiology

Volumn 198, Issue 3, 1996, Pages 881-887

  Vogl, Thomas J ^a   Hammerstingl, Renate ^a   Schwarz, Wolfram ^a   Mack, Martin G ^a   Müller, Petra K ^a   Pegios, Wassilios ^a   Keck, Heiko ^a   Eibl Eibesfeldt, Andreas ^b   Hoelzl, Jürgen ^b   Woessmer, Benoit ^c   Bergman, Clifford ^a   Felix, Roland ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Laboratoire Guerbet   (France)

Author keywords

Iron; Liver neoplasms; Liver, MR; Magnetic resonance (MR), contrast enhancement; Receiver operating characteristic curve (ROC)

Indexed keywords

GADOLINIUM PENTETATE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER HYPERPLASIA; LIVER METASTASIS; LIVER TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PRIORITY JOURNAL; SIGNAL DETECTION;

EID: 0029671183     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.198.3.8628887     Document Type: Article

References (25)

1. Rozneman Y, Zou XM, Kantor HL. Signal loss induced by superparamagnetic iron oxide particles in NMR spin-echo images: the role of diffusion. Magn Reson Med 1990; 14:31-39.
2. Majumdar S, Zoghbi SS, Gore JC. The influence of pulse sequence on the relaxation effects of superparamagnetic iron oxide contrast agents. Magn Reson Med 1989; 10:289-301.
3. Majumdar S, Zoghbi S, Pope CF, Gore JC. Quantification of MR relaxation effects of iron oxide particles in liver and spleen. Radiology 1988; 169:653-655.
4. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989; 152:167-173.
5. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988; 168:297-301
6. Marchai G, Van HP, Demaerel P, et al. Detection of liver metastases with superparamagnetic iron oxide in 15 patients: results of MR imaging at 1.5 T. AJR 1989; 152:771-775.
7. Hahn PF, Stark DD, Weissleder R, Elizondo G, Saini S, Ferrucci JT. Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 1990; 174:361-366.
8. Ros P. Efficacy of superparamagnetic iron oxide as an adjunct to MR imaging of the liver: results of a multicenter trial (abstr). Radiology 1993; 185(P):202.
9. Bruel J, European SPIO Collaborative Study Group. Superparamagnetic iron oxide for the detection of hepatic lesions with MR imaging: results of phase III trial (abstr). Radiology 1993; 189(P):273.
10. Duda S, Laniado M, Kopp A, et al. Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging. JMRI 1994; 4:309-314.
11. Vogl TJ, Hammerstingl R, Pegios W, et al. The value of the liver-specific superparamagnetic contrast medium AMI-25 for the detection and differential diagnosis of primary liver tumors versus metastases. ROFO 1994; 160: 319-328.
12. Hamm B, Reichel M, Vogl T, Taupitz M, Wolf KJ. Superparamagrietic iron oxide particles: clinical results in MR imaging of liver metastases. ROFO 1994; 160:52-58.
13. Denys A, Arrive L, Servois V, et al. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994; 193:665-669.
14. Bellin M, Zaim S, Auberton E, et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994; 193:657-663.
15. Fretz CJ, Stark, DD, Metz, CE, et al. Detection of hepatic metastases: comparison of contrastenhanced CT, unenhanced MR imaging, and iron oxide-enhanced MR imaging. AJR 1990; 155:763-770.
16. Grangier C, Tourniaire J, Mentha G, et al. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994; 18:888-896.
17. Metz C. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-298.
18. Fretz CJ, Elizondo G, Weissleder R. Superparamagnetic iron oxide-enhanced MR imaging: pulse sequence optimization for detection of liver cancer. Radiology 1989; 172:393-397.
19. Fahlvik AK, Holtz E, Klaveriess J. Relaxation efficacy of paramagnetic and superparamagnetic microspheres in liver and spleen. Magn Reson Imaging 1990; 8:363-369.
20. Weissleder R. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994; 193:593-595.
21. Kawamori Y, Matsui O, Kadoya M, et al. Differentiation of hepatocellular carcinomas from hyperplastic nodules induced in rat liver with ferrite-enhanced MR imagine. Radiology 1992; 183:65-72.
22. Rummeny E, Weissleder R, Sironi S, et al. Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171:323-326.
23. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186:133-138.
24. Hamm B, Thoeni KF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994; 190:417-423.
25. Semelka, RC, Shoenut JR, Kroeker MA, et al. Focal liver disease: comparison of dynamic contrast-enhanced CT and T2-weighted fatsuppressed, FLASH, and dynamic gadoliniumenhanced MR imaging at 1.5 T. Radiology 1992; 184:687-694.